Aesica Pharmaceuticals Ltd

aesica-pharma.com

Aesica is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms. Our full service, end-to-end pharmaceutical development and manufacturing solution comprises capabilities in formulation development for API and finished dose, manufacturing at all scales and packaging services.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMACY MARKET

HORUS PHARMA AND PLASTIC BANK COLLABORATE TO RECYCLE NEARLY 100 TONS OF PLASTIC

Horus Pharma | January 11, 2023

news image

On January 10, 2023, Horus Pharma, an independent French ophthalmology laboratory known for its preservative-free eye and eyelid health products, announced a partnership with Plastic Bank to recycle approximately 100 tons of plastic annually. The pact is a part of Horus Pharma's environmental program, Eco' Ophtalmo. Since its founding in 2003, corporate social responsibility (CSR) has been a consistent part of Horus Pharma's culture. Over the years, the company's...

Read More

Business Insights, PHARMACY MARKET

ENDO LAUNCHES AUTHORIZED GENERIC VERSION OF NOXAFIL® (POSACONAZOLE) ORAL SUSPENSION

Prnewswire | April 04, 2023

news image

Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S. "Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "This newly available Noxafil® AG do...

Read More

Pharma Tech

DOUGLAS PHARMACEUTICALS FORMS LEAD PROGRAM R-107 CLINICAL ADVISORY BOARD

Douglas Pharmaceuticals | January 27, 2023

news image

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are ver...

Read More

PHARMA TECH

CORDIS ANNOUNCES THE COMPLETED ACQUISITION OF MEDALLIANCE

PR Newswire | October 03, 2023

news image

Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology. This acquisition adds a key growth driver to the company's coronary and peripheral vascular portfolios as we expect SELUTION SLR&trade...

Read More
news image

Business Insights, PHARMACY MARKET

HORUS PHARMA AND PLASTIC BANK COLLABORATE TO RECYCLE NEARLY 100 TONS OF PLASTIC

Horus Pharma | January 11, 2023

On January 10, 2023, Horus Pharma, an independent French ophthalmology laboratory known for its preservative-free eye and eyelid health products, announced a partnership with Plastic Bank to recycle approximately 100 tons of plastic annually. The pact is a part of Horus Pharma's environmental program, Eco' Ophtalmo. Since its founding in 2003, corporate social responsibility (CSR) has been a consistent part of Horus Pharma's culture. Over the years, the company's...

Read More
news image

Business Insights, PHARMACY MARKET

ENDO LAUNCHES AUTHORIZED GENERIC VERSION OF NOXAFIL® (POSACONAZOLE) ORAL SUSPENSION

Prnewswire | April 04, 2023

Endo International plc announced that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping the authorized generic (AG) version of Merck's Noxafil® (posaconazole) 200 mg/5 mL oral suspension in the U.S. "Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "This newly available Noxafil® AG do...

Read More
news image

Pharma Tech

DOUGLAS PHARMACEUTICALS FORMS LEAD PROGRAM R-107 CLINICAL ADVISORY BOARD

Douglas Pharmaceuticals | January 27, 2023

A clinical advisory board has been established to support Douglas Pharmaceuticals' lead program R-107, an oral extended-release dose of racemic ketamine being developed as an adjunctive or stand-alone therapy for treatment-resistant depression. Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company specializing in the development of specialty generic and repurposed medications (TRD). Peter Surman, Chief Scientific Officer expressed, "We are ver...

Read More
news image

PHARMA TECH

CORDIS ANNOUNCES THE COMPLETED ACQUISITION OF MEDALLIANCE

PR Newswire | October 03, 2023

Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, today announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology. This acquisition adds a key growth driver to the company's coronary and peripheral vascular portfolios as we expect SELUTION SLR&trade...

Read More

Resources

resource image

VIEWS AND ANALYSIS, PHARMACY MARKET

MEETING CURRENT AND FUTURE SERIALISATIONCHALLENGES

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us